Novartis Bolsters I-O Discovery Pipeline With Surface Oncology Deal
This article was originally published in Scrip
Executive Summary
Novartis AG has made a new addition to its ever growing immuno-oncology portfolio, this time licensing four pre-clinical programs from Cambridge, Massachusetts-based biotech Surface Oncology, in a deal worth more than $170m.
You may also be interested in...
Deal Watch: GSK Makes $85m Wager On Surface’s Preclinical NK Cell Therapy
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Start-Up Quarterly Statistics: A Record-Breaking Q2 As Financings Surge
Biopharma start-ups had a record-breading quarter in terms of fundraising. A review of biopharma start-up deal-making and financing activity from April through June 2018, based on data from Strategic Transactions.
IPO Update: Returns Halved As Two Biopharmas Go Public In April; Unity Is May's First
Only two drug developers launched offerings in April and the average 2018 IPO return was just 9% – half the first quarter average – at the end of last month. Unity's May 1 offering was the 17th biopharma IPO this year.